Cambrex invests in Sweden
Small molecule CDMO Cambrex is to spend $3.6 million to increase flexible drug substance manufacturing capacity by 6 m3 (25%) at Karlskoga, Sweden, in response to growing demand for commercial-scale API manufacturing. Engineering work has already commenced and should be completed by November.
The work includes converting a previously customer-dedicated manufacturing train for general use, modifying a four-reactor configuration and installing new holding tanks and a 4 m2 Hastelloy Rosemund filter. Last year, Cambrex added a new 600 m2 process and analytical development facility and a 3,000 m2 logistics centre at the site, which employs over 400.